Want to see INO full AI Analyst Report?
Inovio Pharmaceuticals (INO) Ratios
Inovio Pharmaceuticals Ratios
INO's free cash flow for Q2 2026 was $-18.05M. For the 2026 fiscal year, INO's free cash flow was decreased by $-3.00 and operating cash flow was $-18.05M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.40 | 2.77 | 3.60 | 3.25 | 6.82 |
| Quick Ratio | 1.40 | 2.77 | 3.60 | 3.25 | 6.82 |
| Cash Ratio | 1.01 | 1.86 | 0.34 | 0.48 | 1.08 |
| Solvency Ratio | -1.63 | -2.33 | -2.46 | -2.17 | -3.11 |
| Operating Cash Flow Ratio | -2.03 | -2.95 | -2.92 | -2.23 | -3.28 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -7.42 | 0.00 | 0.00 |
| Net Current Asset Value | $ 10.91M | $ 53.14M | $ 99.51M | $ 189.07M | $ 352.17M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.13 | 0.10 | 0.18 | 0.09 | 0.07 |
| Debt-to-Equity Ratio | 0.39 | 0.17 | 0.26 | 0.14 | 0.08 |
| Debt-to-Capital Ratio | 0.28 | 0.15 | 0.20 | 0.13 | 0.08 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.07 | 0.04 |
| Financial Leverage Ratio | 3.08 | 1.65 | 1.46 | 1.57 | 1.24 |
| Debt Service Coverage Ratio | 0.00 | -584.52 | -7.25 | -216.04 | -153.14 |
| Interest Coverage Ratio | 0.00 | -632.05 | -117.71 | -213.38 | -155.55 |
| Debt to Market Cap | 0.00 | 0.00 | 0.12 | 0.04 | 0.00 |
| Interest Debt Per Share | 0.20 | 0.44 | 1.42 | 1.68 | 0.16 |
| Net Debt to EBITDA | 0.43 | 0.52 | -0.12 | 0.05 | 0.13 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -130000.00% | -49172.60% | -16092.90% | -2693.35% | -16976.28% |
| EBITDA Margin | -125425.94% | -47735.19% | -15671.81% | -2639.80% | -16709.72% |
| Operating Profit Margin | -132871.32% | -51616.91% | -17300.28% | -2607.35% | -16972.34% |
| Pretax Profit Margin | -130000.00% | -49254.27% | -16239.87% | -2726.67% | -17109.87% |
| Net Profit Margin | -130000.00% | -49254.27% | -16239.87% | -2726.67% | -17109.87% |
| Continuous Operations Profit Margin | -130000.00% | -49254.27% | -16239.87% | -2726.67% | -17109.87% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 97.84% | 95.42% | 93.87% | 104.58% | 100.81% |
| Return on Assets (ROA) | -114.31% | -94.75% | -79.04% | -80.28% | -61.23% |
| Return on Equity (ROE) | -352.53% | -156.57% | -115.14% | -125.84% | -75.98% |
| Return on Capital Employed (ROCE) | -283.35% | -144.34% | -112.12% | -106.32% | -70.02% |
| Return on Invested Capital (ROIC) | -259.45% | -139.85% | -97.55% | -105.15% | -69.60% |
| Return on Tangible Assets | -114.31% | -94.75% | -79.04% | -83.31% | -62.90% |
| Earnings Yield | -104.12% | -215.78% | -99.57% | -75.17% | -2.36% |
| Efficiency Ratios | |||||
| Receivables Turnover | 145.21 | 0.18 | 0.35 | 0.87 | 0.22 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.01 | 0.02 | 0.06 | 0.57 | 0.06 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.01 | 0.03 | 0.00 |
| Cash Conversion Cycle | 2.51 | 2009.84 | 1055.17 | 417.50 | 1651.88 |
| Days of Sales Outstanding | 2.51 | 2009.84 | 1055.17 | 417.50 | 1651.88 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 2.51 | 2009.84 | 1055.17 | 417.50 | 1651.88 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.89 | -3.83 | -5.61 | -10.87 | -1.01 |
| Free Cash Flow Per Share | -1.90 | -3.85 | -5.62 | -10.92 | -1.01 |
| Dividend Paid and CapEx Coverage Ratio | -310.22 | -213.35 | -387.55 | -223.10 | -175.23 |
| Capital Expenditure Coverage Ratio | -310.22 | -213.35 | -387.55 | -223.10 | -175.23 |
| Operating Cash Flow Coverage Ratio | -9.46 | -8.77 | -4.12 | -6.74 | -6.53 |
| Operating Cash Flow to Sales Ratio | -1356.37 | -477.95 | -149.48 | -21.07 | -121.54 |
| Free Cash Flow Yield | -108.99% | -210.37% | -91.88% | -58.34% | -1.69% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.96 | -0.46 | -1.00 | -1.33 | -42.32 |
| Price-to-Sales (P/S) Ratio | 1248.52 | 228.26 | 163.10 | 36.27 | 7241.33 |
| Price-to-Book (P/B) Ratio | 3.39 | 0.73 | 1.16 | 1.67 | 32.16 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.92 | -0.48 | -1.09 | -1.71 | -59.24 |
| Price-to-Operating Cash Flow Ratio | -0.92 | -0.48 | -1.09 | -1.72 | -59.58 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | 0.01 | 0.02 | -0.00 | -1.29 |
| Enterprise Value Multiple | -0.57 | 0.04 | -1.16 | -1.32 | -43.21 |
| Enterprise Value | 46.68M | -4.24M | 151.60M | 358.00M | 12.81B |
| EV to EBITDA | -0.57 | 0.04 | -1.16 | -1.32 | -43.21 |
| EV to Sales | 714.34 | -19.49 | 182.21 | 34.88 | 7219.85 |
| EV to Free Cash Flow | -0.52 | 0.04 | -1.22 | -1.65 | -59.06 |
| EV to Operating Cash Flow | -0.53 | 0.04 | -1.22 | -1.66 | -59.40 |
| Tangible Book Value Per Share | 0.51 | 2.52 | 5.29 | 10.55 | 1.80 |
| Shareholders’ Equity Per Share | 0.51 | 2.52 | 5.29 | 11.18 | 1.86 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.01 | 0.04 | 0.52 | 0.01 |
| Net Income Per Share | -1.81 | -3.95 | -6.09 | -14.07 | -1.41 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.01 | 1.01 | 1.01 |
| Research & Development to Revenue | 829.57 | 347.27 | 104.18 | 18.29 | 140.44 |
| SG&A to Revenue | 500.14 | 169.90 | 57.19 | 8.79 | 30.29 |
| Stock-Based Compensation to Revenue | 57.48 | 30.29 | 13.31 | 2.20 | 14.84 |
| Income Quality | 1.04 | 0.97 | 0.92 | 0.77 | 0.71 |
Currency in USD
